New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
Wired
The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.
Read the full story
This is a short summary. The complete article is published by Wired.
Headline and summary aggregated from public news feeds. For information only — not financial advice.